In the GeparNuevo trial, a trend towards higher pCR rates in tumors positive for PD-L1 at baseline was observed, which was significant for PD-L1-tumor cells in the durvalumab arm (p = 0.045) and for PD-L1-immune cells in the placebo arm (p = 0.040), suggesting that high levels of PD-L1 were linked to a stronger response but were not predictive of durvalumab response [15]. The gene discussed is CD274; the disease is neoplasm.